Powered by science.
Driven by impact.
Our mission is to fully understand the molecular behavior of cancer cells, so they can be rationally targeted and specifically eliminated.
To achieve this, we have assembled a multi-disciplinary team of scientists, computational biologists and clinicians. Together, we have decades of experience at leading institutions across clinical oncology, drug development, genomics, and technology.
Our leadership
Edward Larkin
Chief Executive Officer
Edward is the founder and CEO of Valius. He built the healthcare business at Palantir Technologies and led investments into public & private life sciences companies at Dragoneer Investment Group. Edward received a BS summa cum laude from the University of Notre Dame, an MS from the London School of Economics, and completed a year of the MD program at the University of Pennsylvania School of Medicine.
Sarah Hesse, PhD
Head of Translational Science
Sarah is co-founder and Head of Translational Science. Prior to Valius, she led immuno-oncology translational science teams at Takeda. Prior to Takeda, Sarah was a computational biologist at Intellia Therapeutics. Sarah received her PhD in bioengineering from MIT, where she focused on cytokine signaling and systems immunology in Doug Lauffenburger’s lab. She received her BS in chemical engineering from Johns Hopkins.
B. Arman Aksoy, PhD
VP of Computational Biology
Arman's experience in oncology spans computational biology, immunology, translational science, and software engineering. Prior to Valius, Arman led computational biology at Obsidian Therapeutics, and his prior work focused on developing algorithms to facilitate personalized therapies based on patient genomic data. Arman received his PhD in Computational Biology at Memorial Sloan Kettering Cancer Center.
Mark Gustaferro
VP of Operations & Finance
Mark is Vice President of Operations & Finance at Valius. He previously worked as a consultant at Bain & Company and an operational lead at Scale Venture Partners, working closely with high-growth portfolio companies. Mark graduated summa cum laude from Yale University with a degree in economics.
Yannis Valtis, MD
Memorial Sloan Kettering Cancer Center
Ansuman Satpathy, MD, PhD
Stanford University
Kole Roybal, PhD
University of California, San Francisco
James Lee, MD
University of California, San Francisco
Santosh Kesari, MD, PhD
Asthra Health & Lundquist Institute
We're hiring.
Our team combines scientific excellence with the clarity of purpose that comes from working directly with patients. If you appreciate both startup speed and clinical rigor, we’d love to talk.
